ClinicalTrials.gg
CompletedNCT02111564MARINERUpdated Nov 25, 2019Results posted

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

A Phase 3 interventional study of Rivaroxaban, 10 mg and Rivaroxaban, 7.5 mg in Heart Failure, Respiratory Insufficiency and Stroke Acute, sponsored by Janssen Research & Development, LLC. Completed at 617 sites in 37 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,024
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Heart Failure by Johnson & Johnson — 3 open to participants now, 5 under way, none of them phase 3. Heart Failure · Johnson & Johnson.

Enrollment
Largest of 33
12,024 · median 91
Started
2014
with 2 others
Phase 3
12 of 42
none open now
Registered
28th of 42
by date

Among the 42 studies in Heart Failure by Johnson & Johnson, this one has the largest enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 28th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 42 studies in Heart Failure by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Heart Failure by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.

Read the detailed description

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for venous thromboembolism (VTE). The study is designed to evaluate rivaroxaban in the prevention of symptomatic VTE events and VTE-related deaths for a period of 45 days post-hospital discharge. The study will consist of a screening phase, a 45-day double-blind treatment phase, and a 30-day follow-up phase. Study drug will start at randomization (Day 1), and will continue until Day 45 (inclusive). A total of approximately 12000 patients will be randomly assigned to either rivaroxaban or placebo in a 1:1 ratio. The total duration for a patient who completes the study after randomization is expected to be 75 days.

03

Conditions studied

  • Heart Failure
  • Respiratory Insufficiency
  • Stroke Acute
  • Infectious Diseases
  • Rheumatic Diseases

Keywords

  • Heart Failure
  • Respiratory Insufficiency
  • Stroke Acute
  • Infectious Diseases
  • Rheumatic Diseases
  • Medically ill Patient
  • Rivaroxaban
  • Thromboembolism
  • Prophylactic Anti-Coagulation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The duration of the index hospitalization must have been at least 3 and no more than 10 consecutive days
  • Must meet venous thromboembolism (VTE) risk criteria with a total modified Improve VTE Risk Score of: greater than or equal 4, or 3 with D-dimer > 2* (ULN), or 2 with D-dimer > 2*ULN

Key Exclusion Criteria:

  • Any serious bleeding within 3 months prior to randomization or occurring during index hospitalization
  • Serious trauma (including head trauma) within 4 weeks before randomization
  • History of hemorrhagic stroke at any time in the past
  • Any medical condition that requires chronic use of any parenteral or oral anticoagulation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
12,024 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.

    Drug: Rivaroxaban, 10 mg · Drug: Rivaroxaban, 7.5 mg

  • Placebo comparator
    Placebo

    Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.

    Drug: Placebo

Interventions

  • Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.

    Also known as: Xarelto, BAY59-7939

  • Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.

    Also known as: Xarelto, BAY59-7939

  • DrugPlacebo

    All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.

06

What researchers measure

Primary outcomes

  1. Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)

    Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

    Time frame: Up to Day 45

  2. Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC

    A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days.

    Time frame: From randomization to 2 days after the last dose (Day 45)

Secondary outcomes

  1. Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC

    Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

    Time frame: Up to Day 45

  2. Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC

    Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

    Time frame: Up to Day 45

  3. Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC

    Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

    Time frame: Up to Day 45

  4. Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC

    Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

    Time frame: Up to Day 45

  5. Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC

    Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

    Time frame: Up to Day 45

07

Results

Posted Nov 25, 2019
Limitations and caveats
Study was stopped prior to achieving preplanned 161 participants with primary outcome events. Other limitations included how VTE-related death was defined and participants with moderate renal impairment may have been under-dosed.

Participant flow

12024 participants were randomized (rivaroxaban-6007;placebo-6017). 5 participants in placebo were excluded(2 invalid consent,3 randomized before Health Authority approval).

Participant flow — Overall Study
MilestoneRivaroxaban 10 mg or 7.5 mgPlacebo
Started60076012
Treated59825980
Completed58765869
Not completed131143
Withdrew: Death109120
Withdrew: Lost to follow-up23
Withdrew: Withdrawal by subject2020

Outcome measures

PrimaryTime From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)

Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

Time frame:
Up to Day 45
Reported as:
Number · Events per 100 participants in 45 days
Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)
Events per 100 participants in 45 daysRivaroxaban 10 mg or 7.5 mgPlacebo
Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)0.841.11
Statistical analysis
  • Rivaroxaban 10 mg or 7.5 mg vs Placebo · Cox proportional hazards model · p = 0.136 · Hazard ratio (hr): 0.76 · 95% CI 0.52 to 1.09
PrimaryEvent Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC

A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days.

Time frame:
From randomization to 2 days after the last dose (Day 45)
Reported as:
Number · Events per 100 participants in 45 days
Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC
Events per 100 participants in 45 daysRivaroxaban 10 mg or 7.5 mgPlacebo
Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC0.280.15
Statistical analysis
  • Rivaroxaban 10 mg or 7.5 mg vs Placebo · Cox proportional hazards model · p = 0.124 · Hazard ratio (hr): 1.88 · 95% CI 0.84 to 4.23
SecondaryEvent Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC

Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

Time frame:
Up to Day 45
Reported as:
Number · Events per 100 participants in 45 days
Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC
Events per 100 participants in 45 daysRivaroxaban 10 mg or 7.5 mgPlacebo
Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC0.720.77
Statistical analysis
  • Rivaroxaban 10 mg or 7.5 mg vs Placebo · Cox proportional hazards model · p = 0.751 · Hazard ratio (hr): 0.93 · 95% CI 0.62 to 1.42
SecondaryEvent Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

Time frame:
Up to Day 45
Reported as:
Number · Events per 100 participants in 45 days
Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC
Events per 100 participants in 45 daysRivaroxaban 10 mg or 7.5 mgPlacebo
Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC0.190.42
Statistical analysis
  • Rivaroxaban 10 mg or 7.5 mg vs Placebo · Cox proportional hazards model · p = 0.023 · Hazard ratio (hr): 0.44 · 95% CI 0.22 to 0.89
SecondaryEvent Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

Time frame:
Up to Day 45
Reported as:
Number · Events per 100 participants in 45 days
Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC
Events per 100 participants in 45 daysRivaroxaban 10 mg or 7.5 mgPlacebo
Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC1.311.80
Statistical analysis
  • Rivaroxaban 10 mg or 7.5 mg vs Placebo · Cox proportional hazards model · p = 0.033 · Hazard ratio (hr): 0.73 · 95% CI 0.54 to 0.97
SecondaryEvent Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

Time frame:
Up to Day 45
Reported as:
Number · Events per 100 participants in 45 days
Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC
Events per 100 participants in 45 daysRivaroxaban 10 mg or 7.5 mgPlacebo
Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC1.582.03
Statistical analysis
  • Rivaroxaban 10 mg or 7.5 mg vs Placebo · Cox proportional hazards model · p = 0.073 · Hazard ratio (hr): 0.78 · 95% CI 0.60 to 1.02
SecondaryEvent Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC

Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.

Time frame:
Up to Day 45
Reported as:
Number · Events per 100 participants in 45 days
Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC
Events per 100 participants in 45 daysRivaroxaban 10 mg or 7.5 mgPlacebo
Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC1.191.49
Statistical analysis
  • Rivaroxaban 10 mg or 7.5 mg vs Placebo · Cox proportional hazards model · p = 0.156 · Hazard ratio (hr): 0.80 · 95% CI 0.58 to 1.09

Adverse events

Collected over Up to 75 days (+/-5 days). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban 10 mg or 7.5 mg115/6,007 (1.9%)475/6,007 (7.9%)250/6,007 (4.2%)
Placebo126/6,012 (2.1%)493/6,012 (8.2%)280/6,012 (4.7%)
Most frequent serious events
Showing 10 of 334
Most frequent serious events
EventRivaroxaban 10 mg or 7.5 mgPlacebo
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders81/600777/6012
Cardiac FailureCardiac disorders51/600762/6012
PneumoniaInfections and infestations58/600748/6012
DeathGeneral disorders25/600730/6012
Cardiac Failure CongestiveCardiac disorders24/600725/6012
Cardiac Failure AcuteCardiac disorders14/600714/6012
Atrial FibrillationCardiac disorders13/600710/6012
Cardiac Failure ChronicCardiac disorders13/60078/6012
CellulitisInfections and infestations11/600710/6012
Urinary Tract InfectionInfections and infestations11/600711/6012
Most frequent other events
Most frequent other events
EventRivaroxaban 10 mg or 7.5 mgPlacebo
HeadacheNervous system disorders114/6007147/6012
HypertensionVascular disorders75/600793/6012
DiarrhoeaGastrointestinal disorders69/600752/6012

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban 10 mg or 7.5 mgPlaceboTotal
Mean69.7 ± 10.0669.7 ± 10.2269.7 ± 10.14
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban 10 mg or 7.5 mgPlaceboTotal
Female287728585735
Male313031546284
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rivaroxaban 10 mg or 7.5 mgPlaceboTotal
Hispanic or Latino499482981
Not Hispanic or Latino5490551011000
Unknown or Not Reported182038
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rivaroxaban 10 mg or 7.5 mgPlaceboTotal
American Indian or Alaska Native9514
Asian8816
Native Hawaiian or Other Pacific Islander128123251
Black or African American7157128
White5782580811590
More than one race6915
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(Participants)Rivaroxaban 10 mg or 7.5 mgPlaceboTotal
ARGENTINA120122242
AUSTRALIA454388
AUSTRIA6814
BELARUS6766133
BOSNIA-HERZEGOVINA298299597
BRAZIL464692
BULGARIA7147141428
CANADA212243
COLOMBIA7070140
CROATIA135135270
CZECH REPUBLIC115116231
DENMARK347
ESTONIA5611
GEORGIA8808821762
GERMANY8917
GREECE6665131
HUNGARY275274549
ISRAEL5556111
ITALY7473147
LATVIA154154308
LITHUANIA8282164
MEXICO171532
NETHERLANDS8917
PERU333265
POLAND310309619
PORTUGAL6713
PUERTO RICO011
REPUBLIC OF MACEDONIA451451902
ROMANIA162162324
RUSSIAN FEDERATION5715711142
SERBIA305304609
SOUTH AFRICA103102205
SPAIN192191383
TURKEY353570
UKRAINE426428854
UNITED KINGDOM448
UNITED STATES145145290
08

Study locations

617 sites
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Sheffield, Alabama, United States
  • Scottsdale, Arizona, United States
  • Fort Smith, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Fullerton, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • Orange, California, United States
  • Sacramento, California, United States
  • San Jose, California, United States
  • San Marino, California, United States
  • Santa Ana, California, United States
  • Colorado Springs, Colorado, United States
  • Bridgeport, Connecticut, United States
  • Danbury, Connecticut, United States
  • New Haven, Connecticut, United States
  • Waterbury, Connecticut, United States
  • Washington, District of Columbia, United States
  • Atlantis, Florida, United States
  • Bay Pines, Florida, United States
  • Bradenton, Florida, United States
  • Brandon, Florida, United States
  • Celebration, Florida, United States
  • Clearwater, Florida, United States
  • Daytona Beach, Florida, United States
  • Jacksonville Beach, Florida, United States
  • Jacksonville, Florida, United States
  • Largo, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Saint Cloud, Florida, United States
  • Sebring, Florida, United States
  • Tampa, Florida, United States
  • Vero Beach, Florida, United States
  • Wellington, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Idaho Falls, Idaho, United States
  • Chicago, Illinois, United States
  • Normal, Illinois, United States
  • North Chicago, Illinois, United States
  • Hammond, Indiana, United States
  • Lafayette, Indiana, United States
  • Michigan City, Indiana, United States
  • Des Moines, Iowa, United States
  • Kansas City, Kansas, United States
  • Topeka, Kansas, United States
  • Alexandria, Louisiana, United States
  • Lafayette, Louisiana, United States
  • Metairie, Louisiana, United States
  • Minden, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Slidell, Louisiana, United States
  • Rockport, Maine, United States
  • Annapolis, Maryland, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Royal Oak, Michigan, United States
  • Saginaw, Michigan, United States
  • Troy, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Saint Paul, Minnesota, United States
  • Bridgeton, Missouri, United States
  • Columbia, Missouri, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Atlantic City, New Jersey, United States
  • Bridgewater, New Jersey, United States
  • Marlton, New Jersey, United States
  • Newark, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Buffalo, New York, United States
  • Cortlandt Manor, New York, United States
  • Jamaica, New York, United States
  • Johnson City, New York, United States
  • Manhasset, New York, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Valhalla, New York, United States
  • Durham, North Carolina, United States
  • Greensboro, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Statesville, North Carolina, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Maumee, Ohio, United States
  • Springfield, Ohio, United States

Showing the first 100 of 617 sites across 37 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4. PubMed 26842902 ↗
  • Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 Oct 18;11(20):e026229. doi: 10.1161/JAHA.122.026229. Epub 2022 Oct 7. PubMed 36205248 ↗
  • Spyropoulos AC, Raskob GE, Cohen AT, Ageno W, Weitz JI, Spiro TE, Lu W, Lipardi C, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Sugarmann C, Barnathan ES. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 May 10;145(19):1471-1479. doi: 10.1161/CIRCULATIONAHA.121.057847. Epub 2022 Apr 7. PubMed 35389229 ↗
  • Raskob GE, Spyropoulos AC, Spiro TE, Lu W, Yuan Z, Levitan B, Suh E, Barnathan ES. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 Nov 16;10(22):e021579. doi: 10.1161/JAHA.121.021579. Epub 2021 Nov 10. PubMed 34755519 ↗
  • Jamil A, Jamil U, Singh K, Khan F, Chi G. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups. Crit Pathw Cardiol. 2021 Mar 1;20(1):16-24. doi: 10.1097/HPC.0000000000000232. PubMed 32657973 ↗
  • Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 Jun 30;75(25):3140-3147. doi: 10.1016/j.jacc.2020.04.071. PubMed 32586587 ↗
  • Weitz JI, Raskob GE, Spyropoulos AC, Spiro TE, De Sanctis Y, Xu J, Lu W, Suh E, Argenti D, Yang H, Albanese J, Lipardi C, Barnathan ES. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar;120(3):515-524. doi: 10.1055/s-0039-1701009. Epub 2020 Jan 23. PubMed 31975354 ↗
  • Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26. PubMed 30145946 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Mar 2018, 49 months.

Results were first posted in Nov 2019, 1 year 8 months after primary completion. A results delay was requested in Mar 2019.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 49 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2014
First posted
Apr 11, 2014
StartActual
Jan 7, 2014
Primary completionActual
Mar 6, 2018
CompletionActual
May 3, 2018
Results delay requested
Mar 5, 2019
Results first posted
Nov 25, 2019
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02111564
Collaborators
Bayer
Responsible party
Sponsor
First posted
Apr 11, 2014
Start date
Jan 7, 2014
Primary completion
Mar 6, 2018
Completion
May 3, 2018
Results posted
Nov 25, 2019
Last update
Nov 25, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion